Page 41 - GALENIKA MEDICAL JOURNAL

62. Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez 70. Antonini A, Mancini F, Canesi M, Zangaglia R, Isaias IU, Manfredi L, et
HH, et al; LCIG Horizon Study Group. Continuous intrajejunal infusion al. Duodenal levodopa infusion improves quality of life in advanced
of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease. Neurodegener Dis. 2008;5(3-4):244-6.
Parkinson's disease: a randomised, controlled, double-blind, double-
dummy study. Lancet Neurol. 2014 Feb;13(2):141-9. 71. Lang AE, Rodriguez RL, Boyd JT, Chouinard S, Zadikoff C, Espay AJ, et al.
Integrated safety of levodopa-carbidopa intestinal gel from prospective
63. Murata M, Mihara M, Hasegawa K, Jeon B, Tsai CH, Nishikawa N, et al. clinical trials. Mov Disord. 2016 Apr;31(4):538-46.
Efficacy and safety of levodopa-carbidopa intestinal gel from a study
in Japanese, Taiwanese, and Korean advanced Parkinson's disease 72. Mancini F, Comi C, Oggioni GD, Pacchetti C, Calandrella D, Coletti
patients. NPJ Parkinsons Dis. 2016 Nov 3;2:16020. Moja M, et al. Prevalence and features of peripheral neuropathy in
Parkinson's disease patients under different therapeutic regimens.
64. Slevin JT, Fernandez HH, Zadikoff C, Hall C, Eaton S, Dubow J, et al. Parkinsonism Relat Disord. 2014 Jan;20(1):27-31.
Long-term safety and maintenance of efficacy of levodopa-carbidopa
intestinal gel: an open-label extension of the double-blind pivotal 73. Rispoli V, Simioni V, Capone JG, Golfrè Andreasi N, Preda F, Sette E,
study in advanced Parkinson's disease patients. J Parkinsons Dis. et al. Peripheral neuropathy in 30 duodopa patients with vitamins B
2015;5(1):165-74. supplementation. Acta Neurol Scand. 2017 Dec;136(6):660-7.
65. Murata M, Mihara M, Hasegawa K, Jeon B, Tsai CH, Nishikawa N, et al. 74. Fabbri M, Zibetti M, Beccaria L, Merola A, Romagnolo A, Montanaro
Safety and efficacy of levodopa-carbidopa intestinal gel: results from an E, et al. Levodopa/carbidopa intestinal gel infusion and weight loss in
open-label extension study in Japanese, Korean and Taiwanese patients Parkinson's disease. Eur J Neurol. 2019 Mar;26(3):490-6.
with advanced Parkinson's disease. Ther Adv Neurol Disord. 2018 Feb 75. Ferreira JJ, Katzenschlager R, Bloem BR, Bonuccelli U, Burn D, Deuschl
26;11:1756286418759315. G, et al. Summary of the recommendations of the EFNS/MDS-ES review
66. Fernandez HH, Boyd JT, Fung VSC, Lew MF, Rodriguez RL, Slevin JT, et al. on therapeutic management of Parkinson's disease. Eur J Neurol. 2013
Long-term safety and efficacy of levodopa-carbidopa intestinal gel in Jan;20(1):5-15.
advanced Parkinson's disease. Mov Disord. 2018 Jul;33(6):928-36.
67. Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS,
Klostermann F, et al. Levodopa-carbidopa intestinal gel in advanced Konflikt interesa: Nema
Parkinson's disease: final 12-month, open-label results. Mov Disord.
2015 Apr;30(4):500-9. Primljeno: 20. 01. 2023.
68. Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T, Prihvaćeno: 10. 02. 2023.
et al. Intrajejunal levodopa infusion in Parkinson's disease: a pilot Onlajn: 01. 03. 2023.
multicenter study of effects on nonmotor symptoms and quality of life.
Mov Disord. 2009 Jul 30;24(10):1468-74.
69. Merola A, Zibetti M, Angrisano S, Rizzi L, Lanotte M, Lopiano L.
Comparison of subthalamic nucleus deep brain stimulation and
Duodopa in the treatment of advanced Parkinson's disease. Mov
Disord. 2011 Mar;26(4):664-70.

REVIJALNI RADOVI Galenika Medical Journal, 2023; 2(5):31-39. 39